CRIS

Business Context and Reporting Period

Company: CURIS, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2005
Business Overview: Curis is a therapeutic drug development company focused on modulating regulatory signaling pathways for tissue repair and regeneration. The company operates in a single segment: developmental biology products. It relies heavily on strategic collaborations (Genentech, Wyeth, Ortho Biotech) for funding and commercialization, as it has no commercial products to date and has never been profitable.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Structure Shift: While gross revenues increased 224% to $2.77 million (driven by Genentech, Wyeth, and a new Spinal Muscular Atrophy Foundation grant), the company recorded a $3.3 million contra-revenue charge. This resulted in a net revenue loss of $533,000 for the quarter, compared to positive net revenue of $856,000 in Q1 2004.
• Co-Development Accounting: The contra-revenue reflects the company's election to exercise a co-development option with Genentech for a basal cell carcinoma candidate. Under EITF 01-9, Curis reimburses Genentech for 50% of U.S. development costs, which are recorded as a reduction of revenue rather than an expense.
• Debt Reduction: Long-term debt decreased significantly as the company converted a $3.3 million convertible note from Elan Pharma International into common stock in January 2005.
• Operating Cash Flow: Net cash used in operating activities increased to $5.4 million from $1.5 million in the prior year, primarily due to the net loss and changes in working capital.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes existing capital resources ($45.9 million in cash and marketable securities) are sufficient to fund operations through mid-2007. This includes funding the co-development of the basal cell carcinoma candidate with Genentech.
• Future Costs: The company expects to incur approximately $20 million in development expenses through Phase II clinical trials for the basal cell carcinoma program. Phase II completion is expected in mid-2007.
• New Agreements:
  • Genentech (April 2005): Entered a new drug discovery collaboration with a $3 million upfront fee and up to $6 million in R&D funding.
  • Genentech (April 2005): Amended existing agreement to provide an additional $2 million for solid tumor cancer development.
  • Wyeth: Achieved a preclinical milestone triggering a $250,000 payment.
• Risks:
  • Profitability: The company has an accumulated deficit of $668 million and does not expect to achieve profitability in the foreseeable future.
  • Financing Needs: Additional financing will be required beyond mid-2007, which may be difficult to obtain or result in dilution.
  • Collaborator Dependence: 79% of Q1 2005 gross revenue came from Genentech and Wyeth. Termination of these agreements would severely impact operations.
  • Regulatory Uncertainty: All product candidates are in preclinical or early clinical stages; success is not guaranteed.

Investor Verification Checklist

• Contra-Revenue Impact: Verify the sustainability of the revenue model given the $3.3 million contra-revenue charge that turned positive gross revenue into a net loss.
• Cash Runway: Confirm the $45.9 million liquidity position and the specific burn rate assumptions used to project solvency through mid-2007.
• Genentech Collaboration Terms: Review the specific milestones and termination rights in the new April 2005 agreements to assess future revenue certainty.
• Debt Covenants: Monitor compliance with the Boston Private Bank & Trust Company covenant (minimum working capital ratio), as failure could trigger immediate debt repayment.
• Stock-Based Compensation: Note the reversal of $50,000 in stock-based compensation expense in Q1 2005 due to stock price declines; assess the volatility of this line item.